1The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engi J Med, 1995, 333: 1581-1587.
2Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al; German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA, 2004, 292: 1831-1838,
3Otani H,Togashi H,Jesmin S,et al.Temporal effects of edaravone,a free radical scavenger,on transient ischemia-induced neuronal dysfunction in the rat hippocampus.Eur J Pharmacol. 2005, 512: 129-137.
4Amemiya S,Kamiya T,Nito C,et al.Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats.Eur J Pharmacol, 2005, 516: 125-130.
5Zhang W, Sato K, Hayashi T, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res, 2004, 26: 342-348.
6Margaill I, Plotkine M, Lerouet D. Arlioxidant strategies in the treatment of stroke. Free Radic Biol Med, 2005, 39: 429-443.
7Chan PH. Role of oxidants in isehemic brain damage. Stroke, 1996, 27: 1124-1129.
8Stadtman ER, Oliver CN. Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem, 1991,266: 2005-2008.
9Moro MA, Almeida A, Bolanos JP, et al. Mitochondrial respiratory chain and fxee radical generation in stroke. Free Radic Biol Med, 2005, 39: 1291-1304.
10Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol, 1993, 23 : 21-48.
